All News
Allergic Drug-Induced Arthritis (5.19.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Read ArticleLinks:
Brepocitinib in Active Psoriatic Arthritis
Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.
Read ArticleLinks:
Links:
One in Ten is Bad! (5.12.2023)
This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!
Read ArticleLinks:
Links:
Links:
Links:
Links:
Links:
Links:
National Population Insights (4.28.2023)
Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.
Read ArticleLinks:
Links:
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read ArticleLinks:
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
Read ArticleLinks: